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ulingbo@zzu.edu.cAbstract Plasma quinolone concentrations are not routinely measured in clinical practice.
However, in order to optimize quinolone treatment, monitoring of plasma concentrations could
sometimes be useful particularly in critically ill patients. In this study, anti-sparﬂoxacin antibody
was obtained by immunizing rabbits with sparﬂoxacin conjugated with bovine serum albumin using
isobutyl chloroformate method. After the assay procedure was optimized, the standard curve of
sparﬂoxacin was established. The practical measuring range of the competitive ELISA extended
from 5 ng/mL to 2 mg/mL. The recovery rates and coefﬁcients of variation for rat plasma, urine and
tissues were 87.7–106.2% and 4.8–15.3%, respectively. To demonstrate the potential of the ELISA,
a preliminary pharmacokinetics and tissue distribution study of sparﬂoxacin in rats and
quantitative analysis of sparﬂoxacin in several pharmaceuticals were performed and compared
with high-performance liquid chromatography (HPLC). The experimental data indicated that the
proposed method would be a valuable tool in therapeutic drug monitoring (TDM) for sparﬂoxacin.
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Sparﬂoxacin (SPAR), a third-generation quinolone antimicrobial
drug, is widely used in the treatment of urinary tract infections
due to its excellent activity against various bacteria and good
absorption on oral administration [1]. However, based on
published results [2] and data on ﬁle with the manufacture of
sparﬂoxacin, some adverse effects, including decreased appetite,
vomiting, special sense adverse events and so on, would occur in
some patients. Plasma quinolone concentrations are not routi-
nely measured in clinical practice. However, in order to optimize
quinolone treatment, monitoring of plasma concentrations could
sometimes be useful particularly in critically ill patients.
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high-performance thin-layer chromatography [4], spectropho-
tometric method [5], high-performance liquid chromatography
with ultraviolet [6,7] or ﬂuorescent detection [8], and liquid
chromatography-tandem mass spectrometry [9], have been
applied in such a ﬁeld; however, because of the complexity
and diversity of biological samples, these methods have shown
some disadvantages for the analysis of sparﬂoxacin, such as
time-consuming, high background and requirement of sample
pre-treatment. Moreover, owing to individual characteristics
of the method, it is impossible to simultaneously determine
multiple samples under the same conditions. So, it is necessary
to establish different methods for different test samples, which
made high throughput, real-time sparﬂoxacin detection difﬁcult.
In recent years, because of its lower detection limit, high
speciﬁcity, low background and no requirement of sample pre-
treatment [10], enzyme-linked immunosorbent assay (ELISA)
has been applied for the determination of ﬂuoroquinolone
antibiotics, such as oﬂoxacin [11], peﬂoxacin [12], lomeﬂox-
acin, norﬂoxacin, enroﬂoxacin [13] and ciproﬂoxacin [14,15].
However, few reports on the determination of sparﬂoxacin by
ELISA were reported. Therefore, the aim of this article was to
obtain the antibody of sparﬂoxacin and establish the ELISA
method for determination of sparﬂoxacin by a comparative
simple procedure. On such purpose, anti-sparﬂoxacin anti-
body was obtained by immunizing rabbits with sparﬂoxacin
conjugated directly with bovine serum albumin (BSA) using
isobutyl chloroformate method. A highly simple and sensitive
ELISA for the determination of sparﬂoxacin in biological
samples was developed.2. Materials and methods
2.1. Materials and reagents
Sparﬂoxacin, enroﬂoxacin, lomeﬂoxacin, ciproﬂoxacin, oﬂox-
acin, norﬂoxacin, spiramycin and amoxicillin were purchased
from the National Institute for the Control of Pharmaceutical
and Biological Products (China). Ovalbumin (OVA), bovine
serum albumin (BSA), peroxidase-labeled anti-rabbit IgG,
freund’s complete and incomplete adjuvants were obtained
from Huamei Bioengineering Co. (China). Tetramethybenzi-
dine (TMB) substrate solution was obtained from Amresco
Chemical Co. (USA). Polypropylene plate was purchased
from Corning incorporated Co. (USA). All other chemicals
used were of analytical grade.
Phosphate-buffered saline (PBS, 0.02 M phosphate buffer,
pH 7.2, containing 0.15 M NaCl), coating buffer (0.05 M
carbonate-hydrogen carbonate, pH 9.6), blocking buffer
(0.02 M PBS containing 1% OVA), washing buffer (PBS-T,
0.02 M PBS containing 0.05% Tween 20) were used.
2.2. Preparation of an immunogen for sparﬂoxacin
Firstly, 10 mL of tribytylamine was added to a solution of
sparﬂoxacin (35.7 mg, 0.91 mM) in 1.5 mL of 1,4-dioxane and
the resulting solution was allowed to stand with vigorous
stirring in the condition of no light and at room temperature
for 40 min. 15 mL of isobutyl chloroformate was added slowly
to the above solution and kept the solution with vigorous
stirring for another 40 min at the same conditions.Subsequently, the reaction mixture was added dropwise to
7 mL BSA (123.9 mg, 1.81 mM) in water (pH 8.0), and under
stirring incubated at 4 1C for 24 h. Last, the reaction mixture
was dialyzed against deionized water for 3 days at 4 1C. The
puriﬁed conjugate was lyophilized and used as the sparﬂoxacin
immunogen.
The preparation of the sparﬂoxacin–OVA conjugate as a
coating immunogen was similar to that of the sparﬂoxacin–
BSA conjugate.
2.3. Preparation of sparﬂoxacin antibody
An aliquot containing 2 mg sparﬂoxacin–BSA complex was
emulsiﬁed with an equal volume of Freund’s complete adju-
vant. Two Zealand white rabbits were each given multiple
subcutaneous injections over sites along both sides of their
backs. Booster injections were then given four times at
bi-weekly intervals, using one-half the amount of the dose of
the ﬁrst immunization emulsiﬁed with incomplete Freund’s
adjuvant in the same ratio. After validation of antibody
production by indirect ELISA, blood was collected from
carotid artery. The sera were separated by centrifugation at
3000 rpm for 10 min and stored at 70 1C until use.
2.4. Standard solution preparation
The standard stock solution of sparﬂoxacin (0.5 mg/mL) was
prepared in methanol and stored at 4 1C. Working solutions
were prepared by appropriate dilution of the stock solution
with 0.02 M phosphate buffer (pH 7.2) and eluent for ELISA
and HPLC, respectively.
2.5. ELISA procedure
100 mL of the appropriate dilutions of sparﬂoxacin–OVA in
coating buffer was added to each well of a polystyrene
microtiter plate and incubated overnight at 4 1C. After
incubation, the plates were washed three times with washing
buffer. To reduce nonspeciﬁc binding, 150 mL of blocking
buffer was added to each well and incubated at 37 1C for 2 h
to block the unbound sites on the plastic surface. After
washing the plate three times with washing buffer, 50 mL of
the appropriate dilutions of anti-sparﬂoxacin antibody and
50 mL of the appropriate dilutions of sample solution were
added to each well and incubated for 30 min at 37 1C, the
plates were washed three times with washing buffer once more.
Finally, 100 mL of TMB peroxidase substrate solution was
added to each well. After incubation for 20 min in dark at
room temperate, the reaction was terminated by addition of
50 mL of 2 M H2SO4. The activity of enzyme bound to the
plate was measured spectrophotometrically at 450 nm using a
microplate reader.
2.6. HPLC method
HPCL analysis was performed using an Agilent 1200 system,
equipped with an Agilent UV–vis detector setting 290 nm and
a Chromeleon software (Agilent) for calculation of peak area.
The following conditions were maintained–column: Eclipse
XDB-C18 (150 mm 4.6 mm, 5.0 mm); eluent: acetonitrile-
0.05 M phosphate buffer (pH 2.4) (15:85, v/v); ﬂow rate:
Table 1 Cross-reactivities of anti-sparﬂoxacin antibodies.
Compound Cross-reaction (%)a
Sparﬂoxacin 100.00
Orbiﬂoxacin 51.70
Enroﬂoxacin 1.65
Ciproﬂoxacin o0.01
Lomeﬂoxacin 0.25
Saraﬂoxacin o0.01
Oﬂoxacin o0.01
Norﬂoxacin o0.01
Flumequine o0.01
Spiramycin o0.01
Amoxicillin o0.01
Pipemidic acid o0.01
aDetermined as the amount of compound required for 50%
inhibition of the binding of the antibodies to the solid-phase
antigen, as compared to sparﬂoxacin itself (100%).
Figure 1 ELISA standard curve of sparﬂoxacin. B and B0 are the
percentages of binding in the presence and absence of sparﬂox-
acin, respectively. The logit–log plot is obtained from ln[(B/B0)/
(1B/B0)]. Coating antigen concentration: 1 mg/mL, rabbit anti-
sparﬂoxacin antibody dilution: 1/25600, peroxidase labeled anti-
rabbit IgG dilution: 1/5000.
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the retention time of sparﬂoxacin was 12.5 min.
2.7. Determination of sparﬂoxacin in sparﬂoxacin
pharmaceuticals
Two pills of sparﬂoxacin tablet were ground into powder and
5.0 mg of powder was weighed accurately and added into a
calibrated ﬂask with 10 mL of the mobile phase. After 30 min
of suspending in an ultrasonic bath, the precipitate was
removed by centrifugation at 4000 rpm for 10 min. Five
hundred microliters of the suspernatant was pipetted accu-
rately to 10 mL of the mobile phase and ﬁltered through a
0.2 mm membrane and then analyzed by HPLC. The sample
was diluted 500-fold with PBS for ELISA assay.
2.8. Pharmacokinetics and tissue distribution of
sparﬂoxacin in rats
2.8.1. Animals and drug administration
Male and female Sprague-Dawley rats (25075 g) were
obtained from the Henan Laboratory Animal Center (Zhengzhou,
China). They were kept in an environmentally controlled
breeding room for 5 days before starting the experiments
and fed with standard laboratory food and water. Animals
that received the formulation by oral route were deprived of
food 18 h before experimentation. The protocols for animal
studies were approved by our Institutional Animal Care and
Use Committee. Five rats were orally administered 5 mg/kg
sparﬂoxacin.
2.8.2. Plasma sampling
Thirty minutes before the administration of sparﬂoxacin,
blank blood samples were withdrawn. At predetermined time
(0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36 h) after oral
administration, blood samples were withdrawn via orbit vein
into heparinized centrifuging tubes and then centrifuged at
4000 rpm for 10 min at 4 1C. The separated plasma was frozen
at 20 1C before assay. The plasma was diluted 100-fold with
PBS for measurement by ELISA.
2.8.3. Tissue sampling
For tissue distribution study, 30 rats were assigned randomly
to 15 groups and were administered 30 mg/kg sparﬂoxacin by
oral administration. After withdrawing the blood, the rats
were sacriﬁced to obtain the tissues (heart, liver, spleen, lung,
kidney, stomach, small intestine, and brain) at different time
intervals (0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36 h). The tissue
samples were gently blotted with absorbent paper to remove
surface blood, frozen and stored at 20 1C until analysis.
Samples store period was less than 1 week. On the day of the
assay, tissue samples were allowed to thaw and weighted.
Sterile 0.9% NaCl saline was added to facilitate homogeniza-
tion, which was conducted using an apparatus for approxi-
mately 1 min in an ice bath. The homogenized samples were
transferred to a tube, sonicated for 3 min and centrifuged at
4000 rpm for 10 min. A 100 mL aliquot of the supernatants
was transferred to Eppendorf tubes. Tissue samples were
treated as described for plasma sample to determine sparﬂox-
acin concentration by ELISA.3. Results and discussion
3.1. Antiserum production in rabbits
The conjugate of sparﬂoxacin and BSA was prepared as
described above. Rabbits that were inoculated with the
sparﬂoxacin–BSA conjugate obtained by isobutyl chlorofor-
mate method, provided antibodies suitable for detection of
sparﬂoxacin. The antibody titer reached a plateau after the
sixth booster injection.3.2. ELISA speciﬁcity and sensitivity
Since there are many structurally related compounds present
in quinolone antimicrobial drugs, it is extremely important to
evaluate the speciﬁcity of anti-sparﬂoxacin antibody with
Figure 2 Correlation between the values of sparﬂoxacin obtained
by ELISA and HPLC.
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In general, cross-reactivity is a critical factor to judge the
quality of an antibody and its usefulness. As expected, when
the reactivity towards sparﬂoxacin was referred as 100%, the
anti-sparﬂoxacin antibody showed 51.70% cross-reaction with
orbiﬂoxacin, 1.65% cross-reaction with enroﬂoxacin and
0.25% cross-reaction with lomeﬂoxacin due to their similar
sructures. However, under the same conditions, the reactivities
of the anti-sparﬂoxacin antibody with ciproﬂoxacin, saraﬂox-
acin, oﬂoxacin, norﬂoxacin, ﬂumequine, spiramycin, amoxi-
cillin and pipemidic acid were less than 0.01% (shown in
Table 1).
After the assay procedure was optimized, the standard curve of
sparﬂoxacin was established. When the absorbance for each
standard was plotted versus its sparﬂoxacin concentration on a
linear-log scale, a sigmoidal curve was obtained and plotting logit
(B/B0) versus Ig standard sparﬂoxacin concentration yielded a
linear response, the linear regression equation and correlation
coefﬁcient were y¼0.7019xþ1.6756 and 0.996, respectively
(Fig. 1). The practical measuring range of the competitive ELISA
extended from 5 ng/mL to 2 mg/mL samples.
The rat plasma, urine and tissue samples to which known
concentration of sparﬂoxacin (20, 100, 200 mg/mL) had been
spiked were 100-fold diluted with PBS and subjected to
ELISA assay without further treatment. The recovery ratesTable 3 Analytical methods for determination of sparﬂoxacin in
Methods Linear range Limit of
detection (ng/mL)
Spectrophotometric 2–12 mg/mL –
HPLC 50–2000 ng/mL 50
LC/MS 10–1000 ng/mL 2
ELISA 5–2000 ng/mL 5
Table 2 Percent recovery of sparﬂoxacin from plasma, urine and
Samples SPAR in spike
(ng/mL)
Measured
Plasma 200 211.217
1000 1062.037
Urine 200 194.057
1000 981.037
Liver 200 200.567
2000 1785.107
Kidney 200 175.327
2000 2015.317
Lung 200 196.177
2000 1960.737
Spleen 200 197.817
2000 2004.757
Heart 200 185.787
2000 1839.847
Brain 200 194.327
2000 1819.897
Stomach 200 186.827
2000 2083.337
Small intestine 200 193.927
2000 2040.397and coefﬁcients of variation for rat plasma, urine and tissues
at two sparﬂoxacin levels were 87.7–106.2% and 4.8–15.3%,
respectively (shown in Table 2). Comparison of the proposed
method with other methods is listed in Table 3. These data
proved that the ELISA is a rapid, simple and sensitive methodbiological samples and pharmaceutical formulations.
Recovery (%) Analytical samples References
92.70–100.00 Tablets [5]
83.36–113.17 Human serum [7]
96.20–110.90 Rat plasma [9]
87.70–106.20 Rat plasma This work
tissues (n¼5).
(ng/mL) Recovery (%) RSD (%)
10.03 105.6 4.8
67.97 106.2 6.4
15.66 97.0 8.1
94.27 98.1 9.6
18.04 100.3 9.0
163.76 89.3 9.2
12.46 87.7 7.1
248.96 102.6 12.1
24.44 98.1 12.5
245.30 98.0 12.5
22.03 98.9 11.1
182.83 100.2 9.1
26.12 92.9 14.1
200.93 92.0 10.9
26.14 97.2 13.5
138.93 91.0 7.6
23.27 93.4 12.5
319.31 104.2 15.3
25.77 96.9 13.3
242.11 102.0 11.9
Table 4 Results of sample determination by ELISA and HPLC (n¼5).
Batch no. HPLC ELISA
Content of total
sparﬂoxacin (%)
RSD (%) Content of total
sparﬂoxacin (%)
RSD (%)
090901 90.34 3.4 94.83 6.5
100402 88.67 2.6 94.77 7.4
20090804 89.12 3.8 93.73 8.9
Table 5 Pharmacokinetic parameters of sparﬂoxacin in
rats after an oral dose of 5 mg/kg a.
Parameter Mean (n¼5)
t1/2a (h) 1.81
t1/2b (h) 12.86
AUC(0–t) (mg h/L) 1.96
AUC(0–N) (mg h/L) 2.17
CL (L/h kg) 2.31
Cmax (ng/mL) 346.06
tmax (h) 3.00
aTwo-compartment model analysis.
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Figure 3 Mean plasma concentration-time proﬁles of sparﬂox-
acin after a single oral administration to rats (n¼5).
Figure 4 Distribution of sparﬂoxacin in tissues after a single oral
administration to rats (n¼5).
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in therapeutic drug monitoring.
3.3. Comparison of ELISA and HPLC
The ELISA method was compared with an HPLC method for
measuring standard samples and pharmaceutical samples. The
HPLC technique analyzed the 8 samples of various sparﬂox-
acin concentrations ranging from 0.5 to 100 mg/mL, showing a
linear relationship between the peak area and the added
sparﬂoxacin dose. ELISA determination was carried out using
these sparﬂoxacin samples, properly diluted to adjust the
drug-concentration in the measurable range of the ELISA.Fig. 2 shows that there was a good correlation between the
values determined by the two methods, and the plot was linear
as predicted by the equation y¼0.9073xþ0.5471, where y is
the concentration value determined by ELISA analysis and x
is that determined by HPLC, the correlation coefﬁcient was
0.998 (n¼3).
Table 4 indicates the concentrations of total sparﬂoxacin in
sparﬂoxacin tablets analyzed by ELISA and HPLC. Although
the concentrations of total sparﬂoxacin determined by ELISA
were a little higher than the values determined by HPLC, most
likely due to the cross-reactivity with the matrix in samples,
the concentrations of sparﬂoxacin determined by ELISA and
HPLC correlated well in general and were in accordance with
China Pharmacopoeia (content 90–110%). Thus, the immu-
noassay is comparable, in terms of accuracy and reproduci-
bility, to the currently available HPLC method.
3.4. Pharmacokinetic study and tissue distribution of
sparﬂoxacin in rats
After oral administration of sparﬂoxacin, blood and tissue
were obtained at the different intervals and the sparﬂoxacin
content in the plasma and tissues was determined by this
ELISA. The mean plasma and tissue concentration-time curve
proﬁles are illustrated in Figs. 3 and 4, respectively. The main
pharmacokinetics parameters of sparﬂoxacin in rats after oral
administration are summarized in Table 5.
In order to further understand tissues distribution of
sparﬂoxacin, the AUC of sparﬂoxacin was also calculated
(shown in Fig. 5). The AUC of sparﬂoxacin in different tissues
showed that sparﬂoxacin was mainly distributed in heart,
kidney and liver, which implied that the distribution of
sparﬂoxacin depends on the blood ﬂow or perfusion rate of the
organ. The high distribution in small intestine and kidney conﬁrms
the reports that sparﬂoxacin has a good absorption and has good
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Figure 5 Area under curve (AUC) of sparﬂoxacin in various
tissues.
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high level in kidney demonstrated that kidney might be the
primary excretion organ of prototype sparﬂoxacin. The lowest
level founded in brain implied that sparﬂoxacin had difﬁculty
crossing the blood–brain barrier.4. Conclusion
In conclusion, the ELISA procedure for sparﬂoxacin reported
here is sensitive, speciﬁc, reproducible, simple and adaptable for
analysis of a large number of biological samples. To some extent,
the ELISA not only can overcome the disadvantages of some
methods, but also can test all the samples under the same
experimental conditions without further sample pre-treatment.
This ELISA will be a valuable tool in TDM and pharmacokinetic
studies.
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